Azole antimycotics and drug interactions in the perioperative period

Current Opinion in Anaesthesiology

Volumn 23, Issue 4, 2010, Pages 411-448

  Saari, Teijo I ^a   Olkkola, Klaus T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

azoles; benzodiazepines; drug interactions; intravenous hypnotics; opioid; pharmacokinetics

Indexed keywords

ALFENTANIL; ATRACURIUM; CISATRACURIUM; CLARITHROMYCIN; DIAZEPAM; DILTIAZEM; ERYTHROMYCIN; ETOMIDATE; FENTANYL; FLUCONAZOLE; GRAPEFRUIT EXTRACT; HYDROXYITRACONAZOLE; ITRACONAZOLE; KETAMINE; KETOCONAZOLE; MIDAZOLAM; MIVACURIUM; OXYCODONE; PAROXETINE; POSACONAZOLE; PROPOFOL; ROCURONIUM; SAQUINAVIR; TERBINAFINE; THIOPENTAL; UNINDEXED DRUG; VECURONIUM; VERAPAMIL; VORICONAZOLE; ZOLPIDEM; ANTIFUNGAL AGENT; CYTOCHROME P450; ENZYME INHIBITOR; PYRROLE DERIVATIVE;

ANESTHESIA INDUCTION; ANESTHESIST; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; CHRONIC PAIN; CONTINUOUS INFUSION; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DEMETHYLATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INTERACTION; DRUG MECHANISM; DRUG OXIDATION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TRANSFORMATION; ENZYME INHIBITION; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; GRAPEFRUIT JUICE; HUMAN; INCIDENCE; INTENSIVE CARE; LIPOPHILICITY; MYCOSIS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATION DEPRESSION; REVIEW; STEADY STATE; STEROIDOGENESIS; SUDDEN DEATH; SURGICAL PATIENT; SUSPENSION; SYSTEMIC MYCOSIS; TABLET; TRANSDERMAL PATCH; URINARY EXCRETION; ANIMAL; DRUG ANTAGONISM; EDITORIAL;

ANIMALS; ANTIFUNGAL AGENTS; AZOLES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MYCOSES; PERIOPERATIVE CARE;

EID: 77954627675     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32833a254d     Document Type: Review

References (76)

1. Spriet I, Meersseman W, de Hoon J, et al. Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med 2009; 35:603-612.
2. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38:41-57.
3. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35:361-390.
4. Å strand E, Astrand B, Antonov K, et al. Potential drug interactions during a three-decade study period: a cross-sectional study of a prescription register. Eur J Clin Pharmacol 2007; 63:851-859.
5. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004; 329:15-19. (Pubitemid 38869995)
6. Blot S, Vandewoude K. Management of invasive candidiasis in critically ill patients. Drugs 2004; 64:2159-2175.
7. Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, et al. Management of invasive pulmonary aspergillosis in nonneutropenic critically ill patients. Intensive Care Med 2007; 33:1694-1703.
8. Svoboda S, Lichtenstern C, Ober MC, et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy 2009; 55:418-424.
9. Meyer E, Schwab F, Gastmeier P, et al. Antifungal use in intensive care units. J Antimicrob Chemother 2007; 60:619-6224.
10. Nivoix Y, Ubeaud-Sequier G, Engel P, et al. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 2009; 10:395-409.
11. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55:481-485.
12. Olkkola KT, Palkama V, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999; 91:681-685.
13. Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006; 79:362-370.
14. Hagelberg NM, Nieminen TH, Saari TI, et al. Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 2009; 65:263-271.
15. Eagling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998; 45:107-114.
16. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48:1441-1458.
17. Eiden C, Peyriere H, Cociglio M, et al. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007; 41:755-763.
18. de Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61 (Suppl 1):27-37.
19. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993; 24:10-27.
20. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:649-663.
21. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47:2788-2795.
22. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38:111-180.
23. Thompson GR 3rd, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med 2009; 30:203-215.
24. Saari TI, Laine K, Neuvonen M, et al. Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008; 64:25-30.
25. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997; 51:415-419.
26. Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT. The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 1998; 87:190-194.
27. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46:2546-2553.
28. Purkins L, Wood N, Greenhalgh K, et al. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003; 56 (Suppl 1):2-9. (Pubitemid 37491727)
29. Purkins L, Wood N, Greenhalgh K, et al. Voriconazole, a novel widespectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56 (Suppl 1):10-16.
30. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570-1572.
31. Tan K, Brayshaw N, Tomaszewski K, et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235-243.
32. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 2009; 53:541-551.
33. Kohl V, Müller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010; 54:207-212.
34. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21:645-653.
35. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27:825-834.
36. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360:1155-1162.
37. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
38. de Groot MJ, Wakenhut F, Whitlock G, Hyland R. Understanding CYP2D6 interactions. Drug Discov Today 2009; 14:964-972.
39. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009; 61:541-558.
40. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38:389-430.
41. Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 2004; 76:452-466.
42. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82:511-516.
43. Saari TI, Laine K, Leino K, et al. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 2006; 80:502-508.
44. Saari TI, Laine K, Bertilsson L, et al. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007; 63:941-949.
45. Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of oral zolpidem. Br J Clin Pharmacol 2007; 63:116-120.
46. Court MH. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 2005; 400:104-116.
47. Oda Y, Hamaoka N, Hiroi T, et al. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 2001; 51:281-285.
48. Heykants JJ, Meuldermans WE, Michiels LJ, et al. Distribution, metabolism and excretion of etomidate, a short-acting hypnotic drug, in the rat. Comparative study of (R)-(+)-(-)-Etomidate. Arch Int Pharmacodyn Ther 1975; 216:113-129.
49. Russo H, Bressolle F. Pharmacodynamics and pharmacokinetics of thiopental. Clin Pharmacokinet 1998; 35:95-134.
50. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in ndemethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001; 29:887-890.
51. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30:853-858.
52. Hagelberg N, Peltoniemi M, Saari TI, et al. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of oral S-ketamine: a two-phase cross-over study in healthy volunteers. Eur J Pain 2010 [Epub ahead of print]. doi: 10.1016/j.ejpain.2009.10.003.
53. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995; 40:270-272.
54. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53:298-305.
55. Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996; 34:400-405.
56. Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64:133-143.
57. Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37:221-225.
58. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999; 66:33-39.
59. Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58:20-28.
60. Ahonen J, Olkkola KT, Neuvonen PJ. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 1996; 10:314-318. (Pubitemid 26228383)
61. Krivoruk Y, Kirinons MT, Wood AJJ, Wood M. Alfenanil disposition in vivo mediated by human CYP3A4 in humans. Anesthesiology 1994; 81:A380.
62. Rowland M, Tozer TN, editors. Elimination, clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore: Williams and Wilkins; 1995. pp. 156-183.
63. Palkama VJ, Neuvonen PJ, Olkkola KT. The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl. Br J Anaesth 1998; 81:598-600.
64. Feierman DE. Identification of cytochrome P450 3A1/2 as the major P450 isoform responsible for the metabolism of fentanyl by rat liver microsomes. Anesth Analg 1996; 2:36-41.
65. Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32:447-454.
66. Saari TI, Grönlund J, Hagelberg N, et al. Itraconazole increases the exposure to oral and intravenous oxycodone. Eur J Clin Pharmacol 2010 [Epub ahead of print]. doi: 10.1007/s00228-009-0775-8.
67. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64:603-611.
68. Grönlund J, Saari TI, Hagelberg N, et al. Exposure to oral oxycodone is increased by simultaneous inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol (in press). doi: 10.1111/ 1365-2125.2010.03653.x.
69. Nieminen TH, Hagelberg NM, Saari TI, et al. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 2009; 110:1371-1378.
70. Soriano SG, Sullivan LJ, Venkatakrishnan K, et al. Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. Br J Anaesth 2001; 86:223-229.
71. Jokinen MJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. Pharmacol Toxicol 2001; 88:187-191.
72. Isohanni MH, Neuvonen PJ, Palkama VJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol 1998; 54:561-565.
73. Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. Basic Clin Pharmacol Toxicol 2004; 95:120-123.
74. Isohanni MH, Neuvonen PJ, Olkkola KT. Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. Pharmacol Toxicol 1999; 84:143-146.
75. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089-1096.
76. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61:2289-2307.